Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (67)

« Back to Publications

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Kibwana E. et al, (2025), Frontiers in Immunology, 16

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children

Natama HM. et al, (2025), The Lancet Infectious Diseases, 25, 495 - 506

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100868 - 100868

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100867 - 100867

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Datoo MS. et al, (2022), The Lancet Infectious Diseases, 22, 1728 - 1736

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Folegatti PM. et al, (2021), Nature Communications, 12

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

de Graaf H. et al, (2021), Frontiers in Immunology, 12

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197

Load More

1
2
3
4
5